Cover Image
Market Research Report

Global Interferons Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 788615
Published Content info 119 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Interferons Market 2019-2023
Published: February 8, 2019 Content info: 119 Pages
Description

About this market

Interferons belong to the family of cytokines, a group of small proteins essential in cell signaling. They are synthesized and delivered by host cells in response to a pathogen's harmful activities. They are generally used for treating immune system-related diseases such as cancer, hepatitis, ADS, multiple sclerosis, genital and perianal warts, and granulomatous disease. Since these therapeutics directly work on the target, they demonstrate higher efficacy than conventional treatments. Therefore, the versatility of this therapeutic class makes it one of the preferred treatment choices by medical practitioners, as well as patients, thereby driving market growth. Interferons have high target affinity, which is expected to increase their demand, thereby driving market growth. Technavio's analysts have predicted that the interferons market will register a CAGR of almost 2% by 2023.

Market Overview

Advent of novel drug delivery and combination therapies

Considering their biological nature, interferons are mostly administered through the intravenous RoA due to which they are associated with side effects such as redness, irritation, and swelling at the injection site. Thus, they can significantly improve patient compliance and help in better management of hepatitis B.

High cost associated with treatment

Treatment cost is one of the major challenges for patients suffering from diseases such as multiple sclerosis and cancer. High treatment cost restricts the adoption of drugs. which reduces patient adherence and poses a challenge to market growth.

For the detailed list of factors that will drive and challenge the growth of the interferons market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be mildly concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30806

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Interferon beta - Market size and forecast 2018-2023
  • Interferon alfa - Market size and forecast 2018-2023
  • Other interferons - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Biogen
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Merck Sharp & Dohme Corp.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Interferon beta - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Interferon beta - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Interferon alfa - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Interferon alfa - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Other interferons - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Other interferons - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Prevalence of cancer types in the US
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Approved biosimilars
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in Asia
  • Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in ROW
  • Exhibit 44: Key leading countries
  • Exhibit 45: Market opportunity
  • Exhibit 46: Decision framework
  • Exhibit 47: Treatment costs of interferon therapeutics used for treatment of various diseases
  • Exhibit 48: Side effects of interferon therapeutics
  • Exhibit 49: Recently approved substitutes to interferons
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Some interferon biosimilars in market
  • Exhibit 52: Vendor landscape
  • Exhibit 53: Landscape disruption
  • Exhibit 54: Vendors covered
  • Exhibit 55: Vendor classification
  • Exhibit 56: Market positioning of vendors
  • Exhibit 57: Bayer AG - Vendor overview
  • Exhibit 58: Bayer AG - Product segments
  • Exhibit 59: Bayer AG - Organizational developments
  • Exhibit 60: Bayer AG - Geographic focus
  • Exhibit 61: Bayer AG - Segment focus
  • Exhibit 62: Bayer AG - Key offerings
  • Exhibit 63: Bayer AG - Key customers
  • Exhibit 64: Biogen - Vendor overview
  • Exhibit 65: Biogen - Product segments
  • Exhibit 66: Biogen - Organizational developments
  • Exhibit 67: Biogen - Geographic focus
  • Exhibit 68: Biogen - Key offerings
  • Exhibit 69: Biogen - Key customers
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 77: Merck KGaA - Vendor overview
  • Exhibit 78: Merck KGaA - Business segments
  • Exhibit 79: Merck KGaA - Organizational developments
  • Exhibit 80: Merck KGaA - Geographic focus
  • Exhibit 81: Merck KGaA - Segment focus
  • Exhibit 82: Merck KGaA - Key offerings
  • Exhibit 83: Merck KGaA - Key customers
  • Exhibit 84: Merck Sharp & Dohme Corp. - Vendor overview
  • Exhibit 85: Merck Sharp & Dohme Corp. - Business segments
  • Exhibit 86: Merck Sharp & Dohme Corp. - Organizational developments
  • Exhibit 87: Merck Sharp & Dohme Corp. - Geographic focus
  • Exhibit 88: Merck Sharp & Dohme Corp. - Segment focus
  • Exhibit 89: Merck Sharp & Dohme Corp. - Key offerings
  • Exhibit 90: Merck Sharp & Dohme Corp. - Key customers
  • Exhibit 91: Validation techniques employed for market sizing
  • Exhibit 92: List of abbreviations
Back to Top